ArticleStem cells international2019
Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma.
Article in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Long-term zinc treatment alters the mechanical properties and metabolism of prostate cancer cells.Cancer cell international · 2024Article
- Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer.BMC urology · 2023Article
- Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2023Article
- A Hybrid Epithelial to Mesenchymal Transition in Ex Vivo Cutaneous Squamous Cell Carcinoma Tissues.International journal of molecular sciences · 2022Article
- Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib withCell cycle (Georgetown, Tex.) · 2022Article
- TGF-β superfamily co-receptors in cancer.Developmental dynamics : an official publication of the American Association of Anatomists · 2022Review
- Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling.Frontiers in pharmacology · 2022Article
- NK cell upraise in the dark world of cancer stem cells.Cancer cell international · 2021Review
- Identification of CD105+ Extracellular Vesicles as a Candidate Biomarker for Metastatic Breast Cancer.The Journal of surgical research · 2021Article
- Heterogenous expression of endoglin marks advanced renal cancer with distinct tumor microenvironment fitness.Cancer science · 2021Article
- Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.Acta pharmaceutica Sinica. B · 2021Review
- Expressions of TWIST1 and CD105 markers in colorectal cancer patients and their association with metastatic potential and prognosis.Diagnostic pathology · 2021Article
- Sohlh2 Inhibits the Malignant Progression of Renal Cell Carcinoma by Upregulating KlothoFrontiers in oncology · 2021Article
- PRRX1 isoform PRRX1A regulates the stemness phenotype and epithelial-mesenchymal transition (EMT) of cancer stem-like cells (CSCs) derived from non-small cell lung cancer (NSCLC).Translational lung cancer research · 2020Article
- Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.Scientific reports · 2020Article
- Epicardial TGFβ and BMP Signaling in Cardiac Regeneration: What Lesson Can We Learn from the Developing Heart?Biomolecules · 2020Review
- Endoglin: Beyond the Endothelium.Biomolecules · 2020Review
- Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners.Cells · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer. We previously reported that CD105(+) subpopulation in human ccRCC tumors possesses tumor cell self-renewal and chemoresistance capability. In this study, we showed that CD105(+) ACHN tumor cells exhibit epithelial mesenchymal transition (EMT) phenotype with high expression of mesenchymal marker N-cadherin and low expression of epithelial marker E-cadherin. They are more motile and invasive compared to the unselected parental ACHN tumor cells. The knockdown of CD105 by RNA interference led to the downregulation of N-cadherin and the upregulation of E-cadherin and reduced motility and invasiveness of CD105(+) cells. Overexpression of stem cell factor MYC in CD105 knocked down cells increased mesenchymal markers and cell motility. However, the CD105(+) population of tumor cells does not exhibit an increase metastatic potential
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.